RAN BioLinks Joins Canada’s Official Delegation to BIO Japan 2025

Tokyo, Japan October 5,2025 RAN BIOLINKS is proud to announce that the company was selected to join the Canadian delegation at BIO International Japan 2025 with Deep Tech Canada, as part of a Canadian life sciences co-innovation and trade mission led by Deep Tech Canada.

The delegation brought together Canadian life sciences and technology companies with Japanese and global stakeholders to foster international collaboration, explore new partnerships, and showcase Canadian innovation in one of the world’s leading life sciences markets.

For RAN BIOLINKS, participation in BIOJapan provided an opportunity to introduce MAESTRO, the company’s AI-enabled clinical research platform, and demonstrate how connected technology can help address some of the operational challenges facing modern clinical trials.

“Being selected to participate in the Canadian delegation was an important milestone for RAN BIOLINKS and an opportunity to represent the innovation being developed here in Canada,” said Rym Ben Othman, CSO and Co-Founder of RAN BIOLINKS. “Our goal was not only to showcase MAESTRO, but also to connect with organizations in Japan and globally that share our vision for making clinical research more connected, efficient, and patient-focused.”

During the mission, RAN BIOLINKS showcased how integrated clinical trial technology can support more efficient research operations, strengthen data and quality oversight, and ultimately contribute to accelerating the development and delivery of new therapies.

The company also used the opportunity to engage with Japanese and international stakeholders and explore potential avenues for cross-border collaboration across clinical research, life sciences, and health technology.

International engagement is an important part of RAN BIOLINKS’ growth strategy as the company continues to expand the reach of its technology and build relationships within global clinical research ecosystems.

“Canada has a strong life sciences and technology community, and international missions like this create an important bridge between Canadian innovators and global partners,” added Rad Aniba, CEO at RAN BIOLINKS “We are proud to bring Canadian innovation to the international stage, being at the Canadian Pavillon in Yokohama and build relationships that can contribute to the future of clinical research.”

About MAESTRO

MAESTRO is RAN BIOLINKS’ integrated clinical research platform, designed to connect clinical trial operations, data, quality, documentation, and other research workflows within a unified environment. The platform incorporates AI-enabled capabilities to support research teams in improving efficiency, data quality, oversight, and operational decision-making.

About RAN BIOLINKS

RAN BIOLINKS Canada Ltd. is a Canadian clinical research technology and services company focused on accelerating clinical trial outcomes through connected data, quality, and operational systems. The company develops technology designed to help clinical research organizations, investigators, and research teams improve efficiency, data quality, oversight, and inspection readiness across the clinical research lifecycle.